Wells Fargo’s Adial Pharmaceuticals ADIL Stock Holding History

Wells Fargo’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11	Hold	6	–	–	﹤0.01%	6921
2025 Q4	$35	Hold	6	–	–	﹤0.01%	6601
2025 Q3	$57	Hold	6	–	–	﹤0.01%	6470
2025 Q2	$48	Hold	6	–	–	﹤0.01%	6586
2025 Q1	$101	Hold	6	–	–	﹤0.01%	6375
2024 Q4	$162	Buy	+6	New	+$156	﹤0.01%	6383
2024 Q2	–	Hold	0	–	-$15	–	6870
2024 Q1	–	Hold	0	–	–	–	7192
2023 Q4	–	Hold	0	–	–	–	7286
2023 Q3	–	Hold	0	–	–	–	7162
2023 Q2	–	Sell	-1	Closed	-$181	–	7114
2023 Q1	$322	Hold	1	–	–	﹤0.01%	6645
2022 Q4	$197	Sell	1 -1	-50%	-$175	﹤0.01%	6624
2022 Q3	$0	Hold	2	–	–	﹤0.01%	6588
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	6448
2022 Q1	$2K	Buy	2 +1	+100%	+$1.37K	﹤0.01%	6641
2021 Q4	$2K	Hold	1	–	–	﹤0.01%	6858
2021 Q3	$3K	Hold	1	–	–	﹤0.01%	6477
2021 Q2	$2K	Hold	1	–	–	﹤0.01%	6518
2021 Q1	$2K	Hold	1	–	–	﹤0.01%	6617
2020 Q4	$1K	Hold	1	–	–	﹤0.01%	6317
2020 Q3	$2K	Hold	1	–	–	﹤0.01%	6116
2020 Q2	$1K	Hold	1	–	–	﹤0.01%	6148
2020 Q1	$1K	Hold	1	–	–	﹤0.01%	6040
2019 Q4	$2K	Hold	1	–	–	﹤0.01%	6148
2019 Q3	$1K	Hold	1	–	–	﹤0.01%	6249
2019 Q2	$1K	Hold	1	–	–	﹤0.01%	6223
2019 Q1	$2K	Buy	+1	New	+$2.98K	﹤0.01%	5844
2018 Q4	–	Hold	0	–	–	–	6249

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

Wells Fargo's ADIL Position: Q1 2026 in Review

Wells Fargo held its Adial Pharmaceuticals (ADIL) position steady in Q1 2026 at 6 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #6921.

Wells Fargo first reported a position in ADIL in Q1 2019 and has held it in 23 quarters since. The position peaked at $3K in Q3 2021. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

Wells Fargo held 6 shares of Adial Pharmaceuticals worth $11 as of Q1 2026.
Wells Fargo left its Adial Pharmaceuticals share count unchanged in Q1 2026.
Adial Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6921 holding.
Wells Fargo first reported a position in Adial Pharmaceuticals in Q1 2019 and has held it in 23 quarters since.
Wells Fargo's Adial Pharmaceuticals position peaked at $3K in Q3 2021.
14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.